Encompass Health (EHC) Up 8.6% Since Last Earnings Report: Can It Continue?

Encompass Health (EHC) reported robust second-quarter 2025 results, with adjusted EPS of $1.40 surpassing estimates by 16.7% and net operating revenues of $1.5 billion exceeding expectations by 2.3%, primarily driven by strong patient revenue per discharge and strategic capacity expansion. Following this performance, the company significantly raised its full-year 2025 guidance across key metrics, including net operating revenues, adjusted EBITDA, adjusted EPS, and free cash flow, while reiterating its aggressive growth targets for new de novo hospitals and bed additions. EHC shares have outperformed the S&P 500, gaining 8.6% since the last earnings report, reflecting positive investor sentiment and upward revisions in analyst estimates.

Analysis

Encompass Health (EHC) delivered a robust second-quarter 2025 performance, signaling strong operational execution and a positive outlook that has driven its shares to outperform the S&P 500 by 8.6% post-earnings. The company reported a significant earnings beat with an adjusted EPS of $1.40, surpassing consensus estimates by 16.7% and growing 26.1% year-over-year. This was supported by a 12% YoY revenue increase to $1.5 billion, which also beat expectations. Key drivers included a 7.2% rise in total discharges and a 4.2% increase in net patient revenue per discharge, both exceeding estimates and indicating healthy demand and pricing power. While these results were partially offset by a 10.4% increase in operating expenses from higher labor costs, the company's profitability remained strong, with adjusted EBITDA growing 17.4% YoY to $318.6 million. Management's confidence is underscored by a significant upward revision to its full-year 2025 guidance across revenue, adjusted EBITDA, and adjusted EPS, with the midpoint of the new EPS range ($5.12-$5.34) implying 18.1% growth from 2024. The company's financial position is solid, evidenced by a 30.5% YoY increase in adjusted free cash flow, ongoing debt reduction, and a commitment to capital returns through a $24.7 million share buyback and an increased quarterly dividend.

Key Decisions for Investors

• Given the strong earnings beat, significantly raised full-year guidance, and reaffirmed long-term growth strategy, investors could view the recent stock appreciation as fundamentally supported and consider the outlook favorable.
• It is crucial to monitor operating expense trends, particularly salaries and benefits, as continued cost pressures could challenge margin expansion despite strong top-line growth.
• Investors should track the company's execution on its capacity expansion plans, such as the target of opening seven de novo hospitals in 2025, as this is central to achieving its multi-year discharge growth targets of 6-8% CAGR.
• The combination of an increased dividend and a substantial remaining buyback authorization of $433 million offers a supportive capital return profile that should be factored into total return analysis.